<SEC-DOCUMENT>0001206774-17-001131.txt : 20170410
<SEC-HEADER>0001206774-17-001131.hdr.sgml : 20170410
<ACCEPTANCE-DATETIME>20170410074025
ACCESSION NUMBER:		0001206774-17-001131
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170410
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170410
DATE AS OF CHANGE:		20170410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		17751644

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron3126139-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549 <BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): </FONT><B><FONT face="Times New Roman" size=2>April 10, 2017</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><FONT face="Times New Roman" size=2>(Exact name of
registrant as specified in its charter)<BR>___________</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or
      other jurisdiction</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission
      File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(IRS
      Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>of
      incorporation)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070<BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code) </FONT></P>
<P align=center><FONT face="Times New Roman" size=2><B>N/A</B><BR>
(Former name or former address, if changed since last report)</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 98%; padding-top: 2pt"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425 under the
      Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 98%; padding-top: 2pt"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12 under the
      Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 98%; padding-top: 2pt"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b)
      under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>
    <TD NOWRAP WIDTH="1%" STYLE="text-align: left; vertical-align: top"></TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 98%; padding-top: 2pt"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
      under the Exchange Act (17 CFR
240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 8.01. Other Events.
</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On April 10, 2017, Geron
Corporation issued a press release entitled &#147;Geron Announces Completion of
Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen.&#148;
A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Item 9.01. Financial
Statements and Exhibits.</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 30pt"><FONT face="Times New Roman" size=2>(d) Exhibits. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><STRONG><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="96%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Press
      release, dated April 10, 2017.</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>1 </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="51%" colSpan=3><FONT face="Times New Roman" size=2>GERON
      CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Date: April
      10, 2017</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="50%" colSpan=2><FONT face="Times New Roman" size=2>/s/ Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Name:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Stephen N.
      Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Title:</FONT></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Executive
      Vice President,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>General
      Counsel and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Corporate
      Secretary</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>EXHIBIT
INDEX</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><STRONG><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="100%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Press release, dated April 10, 2017.</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>geron3126139-ex991.htm
<DESCRIPTION>PRESS RELEASE, DATED APRIL 10, 2017
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<P align=right><B><FONT face=Arial size=2>EXHIBIT 99.1
</FONT></B></P>
<P align=center><B><FONT face=Arial size=2>Press Release, Dated
April 10, 2017 </FONT></B></P>
<IMG src="geron3126139-ex991x1x1.jpg" border=0><BR>
<P align=center><B><FONT face=Arial size=2>Geron Announces Completion of Second
Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
</FONT></B></P>
<P align=center><I><FONT face=Arial size=2>Both IMerge and IMbark Continue in
Lower Risk Myelodysplastic Syndromes and Relapsed or Refractory<BR>Myelofibrosis
</FONT></I></P>
<P align=center><I><FONT face=Arial size=2>Conference Call Scheduled for 8:00
a.m. EDT Today, April 10 </FONT></I></P>
<P align=left><B><FONT face=Arial size=2>MENLO PARK, Calif., April 10, 2017
</FONT></B><FONT face=Arial size=2>-- Geron Corporation (Nasdaq: GERN) today
announced that Janssen Research &amp; Development, LLC has completed the second
internal data reviews of IMerge and IMbark, the clinical trials of the
telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS)
and relapsed or refractory myelofibrosis (MF), respectively. For IMerge, the
benefit/risk profile of imetelstat in the treated patients supports continued
development in lower risk myelodysplastic syndromes. A data package and proposed
trial design refinements are planned to be provided to the FDA. For IMbark, the
current results suggest clinical benefit and a potential overall survival
benefit associated with imetelstat treatment in relapsed or refractory
myelofibrosis; the trial will continue unchanged to evaluate maturing efficacy
and safety data, including an assessment of overall survival. </FONT></P>
<P align=left><B><I><FONT face=Arial size=2>IMerge </FONT></I></B></P>
<P align=left><FONT face=Arial size=2>IMerge (NCT02598661) is a Phase 2/3
clinical trial evaluating imetelstat in transfusion dependent patients with Low
or Intermediate-1 risk MDS who have relapsed after or are refractory to prior
treatment with an erythropoiesis stimulating agent (ESA). The clinical trial is
in two parts: Part 1 is a Phase 2, open-label, single-arm design in
approximately 30 patients and Part 2 is designed to be a Phase 3, randomized,
controlled trial in approximately 170 patients. The primary efficacy endpoint is
the rate of red blood cell transfusion independence lasting at least 8 weeks.
Key secondary endpoints include the rates of red blood cell transfusion
independence lasting at least 24 weeks and hematologic improvement. Part 1 of
the trial is fully enrolled. </FONT></P>
<P align=left><FONT face=Arial size=2>The second internal review of IMerge
included data from the approximately 30 patients enrolled in Part 1. Based on
this second internal review, the Collaboration&#146;s Joint Steering Committee has
determined the following: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>The safety profile was consistent
      with prior clinical trials of imetelstat in hematologic malignancies, and
      no new safety signals were identified. </FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>The benefit/risk profile of
      imetelstat, including assessments of 8-week and 24-week transfusion
      independence and hematologic improvement by erythroid (HI-E) response,
      across multiple MDS subtypes, supports continued development in lower risk
      MDS.</FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>Part 1 of the trial will continue
      unmodified, and patients remaining in the treatment phase may continue to
      receive imetelstat. </FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>A data package, as well as proposed
      refinements to the trial design for Part 2 of IMerge, is planned to be
      provided to the FDA. </FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>Data from Part 1 are expected to be
      submitted for consideration for presentation at a medical conference in
      the future. </FONT></P></TD></TR></TABLE>
<P align=left><FONT face=Arial size=2>Geron expects that FDA feedback and the
totality of imetelstat program information, including an assessment of the
evolving treatment landscape in MDS and the potential application of imetelstat
in multiple hematologic malignancies, will inform Janssen&#146;s decision to initiate
Part 2 of IMerge. If Part 2 of IMerge is initiated, Geron expects this Phase 3 stage
of IMerge to be opened for patient enrollment in the fourth quarter of 2017.
</FONT></P>
<P align=center><FONT face=Arial size=2>1</FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><I><FONT face=Arial size=2>IMbark </FONT></I></B></P>
<P align=left><FONT face=Arial size=2>IMbark (NCT02426086) was originally designed as a Phase 2 clinical trial to evaluate
two dose levels of imetelstat (either 4.7 mg/kg or 9.4 mg/kg administered every three weeks) in approximately 200 patients
with Intermediate-2 or High risk MF who have relapsed after or are refractory to prior treatment with a JAK inhibitor. The
co-primary efficacy endpoints for the trial are spleen response rate (&#8805;35% reduction in spleen volume assessed by imaging)
and symptom response rate (&#8805;50% reduction in Total Symptom Score) at 24 weeks.</FONT></P>
<P align=left><FONT face=Arial size=2>The second internal review of IMbark
included data from the approximately 100 patients who were enrolled in the
trial, with each dosing arm analyzed separately. Based on this second internal
review, the Collaboration&#146;s Joint Steering Committee has determined the
following:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>The safety profile was consistent
      with prior clinical trials of imetelstat in hematologic malignancies, and
      no new safety signals were identified. </FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>The data support 9.4 mg/kg as an
      appropriate starting dose for the relapsed or refractory MF patient
      population. </FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>In these relapsed or refractory MF
      patients treated in the 9.4 mg/kg dosing arm, the spleen volume response
      rate observed to date was less than that reported in front-line MF
      patients treated in trials with other drugs. However, activity within
      multiple outcome measures was observed with imetelstat treatment, which
      suggests clinical benefit in this relapsed or refractory MF patient
      population. These outcome measures included a range of spleen volume
      reductions, decreases in Total Symptoms Score, and improvements in
      hematologic parameters, such as anemia and peripheral blood counts. In
      addition, the data suggest a potential overall survival benefit associated
      with imetelstat treatment in these patients. </FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>The trial will continue without any
      modifications, including conduct of all safety and efficacy assessments as
      planned in the protocol, including overall survival. Patients remaining in
      the treatment phase may continue to receive imetelstat.</FONT></P></TD></TR>
    <TR>
    <TD STYLE="padding-right: 8pt; padding-left: 15pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face=Arial size=2>Enrollment of new patients to the
      trial will remain suspended because the total number of patients enrolled
      to date is adequate to assess longer-term outcome measures when the data
      are fully matured. </FONT></P></TD></TR></TABLE>
<P align=left><FONT face=Arial size=2>During the next year, Geron expects Janssen to
evaluate maturing efficacy and safety data from the trial, including an
assessment of overall survival. Geron expects the longer-term data from the trial,
potential health authority feedback, and the totality of imetelstat program
information, including an assessment of the evolving treatment landscape in MF
and the potential application of imetelstat in multiple hematologic
malignancies, including MDS, will inform Janssen&#146;s decision whether to continue
development of imetelstat in relapsed or refractory MF. </FONT></P>
<P align=left><B><FONT face=Arial size=2>Conference Call </FONT></B></P>
<P align=left><FONT face=Arial size=2>At 8:00 a.m. EDT on April 10, 2017,
Geron&#146;s management will host a conference call to review outcomes from the
second internal data reviews of IMbark and IMerge. Participants can access the
conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195
(international). The conference ID number is 6116409. A live audio-only webcast
is also available through the company&#146;s website at www.geron.com in the
Investors section under Events and at http://edge.media-server.com/m/p/w5mtfw9k.
The audio webcast of the conference call will be available for replay
approximately one hour following the live broadcast through May 11, 2017.
</FONT></P>
<P align=left><B><FONT face=Arial size=2>About Imetelstat </FONT></B></P>
<P align=left><FONT face=Arial size=2>Imetelstat (GRN163L; JNJ-63935937) is a
potent and specific inhibitor of telomerase that is administered by intravenous
infusion. This first-in-class compound, discovered by Geron, is a specially
designed and modified short oligonucleotide, which targets and binds directly
with high affinity to the active site of telomerase. Preliminary clinical data
suggest imetelstat has disease-modifying activity by inhibiting the progenitor
cells of the malignant clones associated with hematologic malignancies in a
relatively select manner. Most commonly reported adverse events in imetelstat
clinical studies include fatigue, gastrointestinal symptoms and cytopenias.
Imetelstat has not been approved for marketing by any regulatory authority.
</FONT></P>
<P align=center><FONT face=Arial size=2>2</FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face=Arial size=2>About the Collaboration with Janssen
</FONT></B></P>
<P align=left><FONT face=Arial size=2>On November 13, 2014, Geron entered into
an exclusive worldwide license and collaboration agreement with Janssen Biotech,
Inc., to develop and commercialize imetelstat for oncology, including
hematologic myeloid malignancies, and all other human therapeutics uses. Under
the terms of the agreement, Geron received an upfront payment of $35 million and
is eligible to receive additional payments up to a potential total of $900
million for the achievement of development, regulatory and commercial
milestones, as well as royalties on worldwide net sales. All regulatory,
development, manufacturing and promotional activities related to imetelstat are
being managed through a joint governance structure, with Janssen responsible for
these activities. The joint governance structure includes a Joint Steering
Committee with equal membership from both companies. </FONT></P>
<P align=left><B><FONT face=Arial size=2>About Geron </FONT></B></P>
<P align=left><FONT face=Arial size=2>Geron is a clinical stage
biopharmaceutical company focused on the collaborative development of a
first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid
malignancies. For more information about Geron, visit www.geron.com. </FONT></P>
<P align=left><B><FONT face=Arial size=2>Use of Forward-Looking Statements
</FONT></B></P>
<P align=left><FONT face=Arial size=2>Except for the historical information
contained herein, this press release contains forward-looking statements made
pursuant to the &#147;safe harbor&#148; provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this press
release regarding: (i) continued development of imetelstat by Janssen for MDS in
Part 2 and continued conduct by Janssen of IMbark and/or IMerge; (ii) data that
suggest clinical benefit and potential overall survival benefit of imetelstat in
MF; (iii) a planned data package will be provided to the FDA for IMerge; (iv)
that Janssen will conduct any additional data reviews for IMbark during the next
year; (v) potential outcomes of any data reviews conducted by Janssen for
IMbark; (vi) any future presentation of data from current clinical trials of
imetelstat by Janssen at a medical conference; (vii) the safety and efficacy of
imetelstat; (viii) that if Janssen decides to proceed with Part 2 of IMerge, the
clinical trial will be open for patient enrollment in the fourth quarter of 2017; (ix) potential
receipt by Geron of additional payments up to a potential total of $900 million
for the achievement of development, regulatory and commercial milestones, and
royalties from sales of imetelstat; and (x) other statements that are not
historical facts, constitute forward-looking statements. These statements
involve risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. These risks and
uncertainties, include, without limitation, risks and uncertainties related to:
(i) whether Janssen decides to initiate Part 2 of IMerge and to continue to
conduct IMerge and/or IMbark; (ii) whether imetelstat is safe and efficacious
and will succeed in IMbark and/or IMerge by overcoming all of the clinical
safety and efficacy, technical, scientific, manufacturing and regulatory
challenges; (iii) whether health authorities permit IMbark and/or IMerge to
continue to proceed under the existing protocols or any amendments thereto; (iv)
Janssen&#146;s ability to collect additional and more mature data from current
clinical trials of imetelstat; (v) Geron&#146;s dependence on Janssen for the
development, regulatory approval, manufacture and commercialization of
imetelstat, including the risks that if Janssen were to breach or terminate the
collaboration agreement or otherwise fail to successfully develop and
commercialize imetelstat and in a timely manner, or at all, Geron would not
obtain the anticipated financial and other benefits of the collaboration
agreement with Janssen and the clinical development or commercialization of
imetelstat could be delayed or terminated; (vi) any future efficacy or safety
results from any clinical trial of imetelstat may cause the benefit/risk profile
of imetelstat to become unacceptable; and (vii) patent coverage of imetelstat
enables Janssen to successfully commercialize imetelstat. Additional information
on the above-stated risks and uncertainties and additional risks, uncertainties
and factors that could cause actual results to differ materially from those in
the forward-looking statements are contained in Geron&#146;s periodic reports filed
with the Securities and Exchange Commission under the heading &#147;Risk Factors,&#148;
including Geron&#146;s annual report on Form 10-K for the year ended December 31,
2016. Undue reliance should not be placed on forward-looking statements, which
speak only as of the date they are made, and the facts and assumptions
underlying the forward-looking statements may change. Except as required by law,
Geron disclaims any obligation to update these forward-looking statements to
reflect future information, events or circumstances.</FONT></P>
<P align=left><B><FONT face=Arial size=2>CONTACT: </FONT></B></P>
<P align=left><FONT face=Arial size=2>Anna Krassowska, Ph.D.<BR>Investor and
Media Relations<BR>650-473-7765<BR>investor@geron.com<BR>media@geron.com
</FONT></P>
<P align=center><FONT face=Arial size=2>### </FONT></P>
<P align=center><FONT face=Arial size=2>3</FONT></P>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron3126139-ex991x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron3126139-ex991x1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q & # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TCXP?%S_@
MK=_P6C_X*W_MM?L=?L<?MN>(_P!@W]FS]@SQ'JW@35]7\"ZQXJ\,ZOJVL>'/
M%%Q\.]2U/4[_ .'4^A>+/&?B/QAXMT/Q;JFD:1JWBS1/"OA[PMH<<-O&-;%S
M<ZQU?[('[2/_  54_P""1W_!7_\ 9_\ ^";'[?W[4>H?MR_!']M?1].E^''Q
M(\3^)/%'BCQ%X3U75;WQ/X?\.:YI&L^.8I_%NDWT/BKPV- \9^!K[6]<\/OH
M^M:=XAT;4#J4;)<>M_\ !OK_ ,IMO^#C/_LZ#7__ %H_]HJL?_@M+_RLG?\
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M0/"7P[\$ZA;W+Q>'K^TU7QGXS\26FAN;:+3;">Y_M K^'?\ 9^_Y73OVJ_\
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M]8/BF&6W_8_\1V\\4D,\'[-FKPS0RHT<L4L7PON$DBDC<!DDC=61T8!E8%6
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
